我們已在上線!
進一步了解
BCEL
Atreca
BCEL
BCEL
已下市
BCEL已於2024年3月18日下市。
關於: Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
員工: 90
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
價格圖表採用Lightweight Charts™實作